Kathleen Kimpton
Sydney, NSW 2052, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
High-throughput 3D engineered paediatric tumour models for precision medicine.
Journal: Molecular systems biology
Published: August 13, 2025
EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer.
Journal: International journal of nanomedicine
Published: November 18, 2023
Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: June 28, 2023
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Journal: Science translational medicine
Published: May 17, 2023
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.
Journal: Cancer research
Published: February 10, 2020
Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma.
Journal: ACS pharmacology & translational science
Published: October 18, 2019
In vivo [64Cu]CuCl2 PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis.
Journal: Theranostics
Published: September 10, 2018
A photoelectrochemical platform for the capture and release of rare single cells.
Journal: Nature communications
Published: December 17, 2017
Dextran-Catechin inhibits angiogenesis by disrupting copper homeostasis in endothelial cells.
Journal: Scientific reports
Published: April 06, 2017
Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
Journal: Oncotarget
Published: September 22, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026